ATE116335T1 - Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2). - Google Patents

Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).

Info

Publication number
ATE116335T1
ATE116335T1 AT89900786T AT89900786T ATE116335T1 AT E116335 T1 ATE116335 T1 AT E116335T1 AT 89900786 T AT89900786 T AT 89900786T AT 89900786 T AT89900786 T AT 89900786T AT E116335 T1 ATE116335 T1 AT E116335T1
Authority
AT
Austria
Prior art keywords
growth factor
igf
acid residue
insulin
pct
Prior art date
Application number
AT89900786T
Other languages
English (en)
Inventor
Francis John Ballard
John Campbell Wallace
Julian Richard Este Wells
Original Assignee
Gropep Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gropep Pty Ltd filed Critical Gropep Pty Ltd
Application granted granted Critical
Publication of ATE116335T1 publication Critical patent/ATE116335T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
AT89900786T 1987-12-24 1988-12-20 Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2). ATE116335T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPI606887 1987-12-24

Publications (1)

Publication Number Publication Date
ATE116335T1 true ATE116335T1 (de) 1995-01-15

Family

ID=3772677

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89900786T ATE116335T1 (de) 1987-12-24 1988-12-20 Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).

Country Status (7)

Country Link
US (1) US5164370A (de)
EP (1) EP0346429B1 (de)
JP (1) JP2507106B2 (de)
AT (1) ATE116335T1 (de)
CA (1) CA1341204C (de)
DE (1) DE3852636T2 (de)
WO (1) WO1989005822A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US6723699B1 (en) 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en) 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
ATE125869T1 (de) * 1989-06-09 1995-08-15 Gropep Pty Ltd Wachstumshormonfusionsproteine.
US5045531A (en) * 1989-12-18 1991-09-03 Magainin Sciences Inc. Wound treatment employing biologically active ion channel forming peptides and proteins
CA2074166C (en) * 1990-02-13 2003-11-25 Francis J. Ballard Method for treating intestinal diseases
US5679771A (en) * 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
SE9002731D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product comprising growth factor
SE9002732D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
US5744139A (en) * 1991-06-28 1998-04-28 University Of Tennessee Research Corporation Insulin-like growth factor I (IGF-1) induced improvement of depressed T4/T8 ratios
AU2368892A (en) * 1991-07-29 1993-03-02 British Bio-Technology Limited Igf-ii analogues
US5288703A (en) * 1991-10-07 1994-02-22 Brigham And Women's Hospital Method for enhancing gut absorption
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
WO1993023067A1 (en) * 1992-05-08 1993-11-25 Thomas Jefferson University Igf-1 analogs
CA2114419A1 (en) * 1992-06-08 1993-12-23 Peter D. Gluckman Use of growth factor igf-i and/or igf-ii
NZ260309A (en) * 1992-06-08 1997-07-27 Pharmacia Ab Substituted For K Use of 1gf-2 for prevention or treatment of nutritional or gastrointestinal disorders and promoting neonatal growth
CA2136969C (en) * 1992-06-12 2009-03-24 Michael E. Lewis Prevention and treatment of peripheral neuropathy
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5444045A (en) * 1992-09-17 1995-08-22 Gropep, Pty. Ltd. Method of administering IGF-1, IGF-2, and analogs thereof to birds
GB9310049D0 (en) * 1993-05-12 1993-06-30 Cancer Res Campaign Tech Growth factor effects
CA2172158A1 (en) * 1993-09-20 1995-03-30 Joseph A. Carlino Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
WO1998011913A1 (en) * 1996-09-16 1998-03-26 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6358916B1 (en) 1998-07-22 2002-03-19 Thomas T. Chen Biological activity of IGF-I E domain peptide
US7700353B2 (en) 1998-07-22 2010-04-20 E-P Therapeutics, Inc. Compositions and methods for inducing apoptosis in tumor cells
US7118752B2 (en) 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
IL143834A0 (en) * 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
EP1506972A1 (de) * 1999-01-06 2005-02-16 Genentech Inc. Mutierte Varianten des Insulin-ähnlichen Wachstumsfaktor-I (IGF-I)
IL143866A0 (en) * 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
CA2369451C (en) * 1999-04-08 2009-09-22 Genentech, Inc. Composition based on oppositely-charged polypeptides
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
DK1358209T3 (da) * 2001-02-09 2007-05-07 Genentech Inc Krystallisering af IGF-1
US7071300B2 (en) * 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
AU2002363322A1 (en) * 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
JP2005534650A (ja) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
CA2541015A1 (en) * 2003-10-03 2005-04-14 Genentech, Inc. Igf binding proteins
EP1674113A1 (de) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
WO2006076342A2 (en) * 2005-01-11 2006-07-20 Heart Failure Technologies, Inc. Method and system for treating heart failure
TWI406870B (zh) 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
WO2007146689A2 (en) 2006-06-09 2007-12-21 Novartis Ag Stabilized insulin-like growth factor polypeptides
CA2756596A1 (en) 2009-03-27 2010-09-30 Proyecto De Biomedicina Cima, S.L. Methods and compositions for the treatment of cirrhosis and liver fibrosis
PT3344758T (pt) 2015-09-01 2021-10-28 Ncardia B V Um método in vitro para diferenciação de uma população de células estaminais pluripotentes humanas numa população de células de cardiomiócitos
US20210008172A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US408518A (en) * 1889-08-06 Stilt
US4196167A (en) * 1978-12-26 1980-04-01 California Medical Developments, Inc. Drug detection device
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
US4745179A (en) * 1984-04-02 1988-05-17 Fujisawa Pharmaceutical Co., Ltd. 59 Valine insulin-like growth factor I and process for production thereof
SE8403479L (sv) * 1984-06-29 1986-01-29 Ssab Svenskt Stal Ab Sett att framstella profilerade stenger
EP0235205B1 (de) * 1985-08-22 1992-10-28 Gropep Pty. Ltd. Peptidanalogedes insulinähnlichen wachstumsfaktors-1 bei säugetieren
SE8505920D0 (sv) * 1985-12-13 1985-12-13 Kabigen Ab New protein and its use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
CA2007886A1 (en) * 1989-01-17 1990-07-17 Marvin L. Bayne Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast

Also Published As

Publication number Publication date
DE3852636T2 (de) 1995-05-04
EP0346429A4 (en) 1990-10-10
EP0346429A1 (de) 1989-12-20
DE3852636D1 (de) 1995-02-09
AU2900989A (en) 1989-07-19
JPH02504279A (ja) 1990-12-06
WO1989005822A1 (en) 1989-06-29
JP2507106B2 (ja) 1996-06-12
CA1341204C (en) 2001-03-13
US5164370A (en) 1992-11-17
AU612776B2 (en) 1991-07-18
EP0346429B1 (de) 1994-12-28

Similar Documents

Publication Publication Date Title
ATE116335T1 (de) Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
AU6286986A (en) Peptide analogues of mammalian insulin-like growth factor-1
DE69016655T2 (de) Biologisch aktive polypeptide, die auf transformierten wachstumsfaktor-beta-sequenzen basieren.
ATE121755T1 (de) Deletionsanaloga von magaininpeptiden.
DE69525544T2 (de) Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose
ATE146188T1 (de) Substituierungsanaloge von magaininpeptiden
MX167236B (es) Peptidos sinteticos de timosina -1 y metodo para su obtencion
NZ224028A (en) Bovine growth hormone analogue compositions and animals
ES2135398T3 (es) Compuesto y composiciones de inhibicion de la resorcion osea.
EP0282318A3 (de) Analog des Rinderwachstumshormons
BR8807658A (pt) Peptideos tendo homologia estrutural, formulacao antigena farmaceutica e processo para alterar as caracteristicas de um vertebrado
KR890700673A (ko) 돼지 성장호르몬 아날로그
AR004497A1 (es) Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica.
DE3882233T2 (de) Gefässaktive peptide.
AR247473A1 (es) Una composicion que produce una respuesta lactogenica o crecimiento en ganado bovino, excluidas todas sus aplicaciones terapeuticas
GB1119353A (en) Peptides having an adrenocorticotropic hormone action and process for their manufacture
JPS5750948A (en) Insulin analog and preparation
RU97117935A (ru) Свойства пептидов, стимулирующих рост
DK661888A (da) Biologisk aktive molekyler
JPS5791965A (en) Preparation of polypeptide
TH21046B (th) ฮอร์โมนเทียมเพื่อการเจริญเติบโตของหมู
TH5744EX (th) โมเลกุลสารออกฤทธิ์ทางชีวภาพ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee